PitchSend

Half-Year 2022 Financial and Clinical Trials Update

Evrysdi Global sales CHFbn CER growth Regional sales +106% CER growth US 0.6 +32% 0.5 0.4 0.3 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 500m • US: Strong growth driven by switch and treatment-naïve patients; market share increasing >20% • EU: Excellent growth driven by Germany and launches in key markets UK, Italy and France . International: Strong growth in all regions CER=Constant Exchange Rates Europe +489% Japan n/a International +65% Roche 184

View entire presentation